Ark slumps after gene therapy Cerepro rejected in EU for brain cancer
21 December 2009
Malini Guha
Ark Therapeutics' Cerepro (sitimagene ceradenovec), which could have become the first gene therapy approved in the EU, has been rejected by the CHMP for the treatment of operable high grade glioma (brain cancer), leading to a 50% fall in the company’s share price on the London Stock Exchange on December...
Please Login to read the full article.
21 December 2009
Malini Guha
Please Login to read the full article.
RELATED CONTENT
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
